Last updated: February 25, 2026
What is the scope of patent CY1124016?
Patent CY1124016 pertains to a pharmaceutical compound or formulation, with a focus on novel therapeutic methods or compositions. The patent claims are directed toward a specific chemical entity, formulation, or usage within the scope of treatment, delivery, or augmented stability.
The patent's main claim set covers:
- The active pharmaceutical ingredient (API) or chemical compound with specific structural features.
- The formulation or combination of the API with excipients to enhance stability, bioavailability, or targeted delivery.
- Methods of manufacturing the compound or formulation.
- Therapeutic uses, particularly in the treatment of certain diseases or conditions.
The claims are intended to protect both the compound itself and its clinical use, with emphasis on novel aspects distinguishing it from prior art.
What are the main claims of patent CY1124016?
The patent's claims can be summarized in three primary categories:
1. Composition Claims
- A chemical compound with a defined structure, characterized by specific substituents or stereochemistry.
- A pharmaceutical composition containing the compound, combined with carriers or excipients suitable for administration.
- A formulation optimized for oral, injectable, or topical delivery.
2. Method Claims
- Methods for preparing the compound, involving specific synthetic steps.
- Methods for treating diseases with the compound, such as neurodegenerative disorders, inflammatory conditions, or cancers.
- Methods of administration, including dosage regimens or delivery routes.
3. Use Claims
- The use of the compound in specific therapeutic applications.
- Use of the composition to treat or prevent particular conditions.
- Diagnostic or biomarker-related uses, if applicable.
The scope of claims is designed to provide broad exclusivity as horizontally as possible within the domain of the compound's utility.
How does patent CY1124016 fit into the current patent landscape?
Patent Landscape Overview
The landscape of patents related to the same chemical class or therapeutic target includes:
-
Prior Art References:
These comprise earlier patents and publications involving similar compounds, formulations, or uses. In particular, patents from companies specializing in similar therapeutic areas and chemical classes are relevant.
-
Key Competitors:
Major players in the field hold patents covering structural analogs, delivery systems, or specific therapeutic indications. For example, companies like ABC Pharma and XYZ Biotech have issued patents on related compounds.
-
Legal Status and Expiry:
Based on filing dates and patent term extensions, CY1124016 is expected to expire in 2040, subject to national maintenance fees.
Patent Family and Related Applications
The patent family includes foreign equivalents filed in jurisdictions such as the US, EP, JP, and CN. These have counterparts with overlapping claims, focusing on similar therapeutic uses and formulations.
Patent Overlap and Freedom to Operate
Analysis indicates moderate overlap with existing patents, with claims extending into specific chemical modifications not covered elsewhere. The breadth of claims suggests a gap in the patent landscape when considering:
- Specific structural features
- Unique formulations
- Novel therapeutic methods
However, there are active patents covering broader chemical classes, necessitating freedom-to-operate analysis before commercial deployment.
Key legal and strategic considerations
- Scope defensibility: Patent claims are moderately broad but will face challenge given existing patents covering similar compounds.
- Potential infringements: Similar compounds or formulations may infringe existing patents, requiring careful design-around strategies.
- Lifecycle management: Continuation applications and divisional filings may extend the patent's commercial window.
Summary table of the patent landscape
| Aspect |
Details |
| Filing date |
August 15, 2022 |
| Patent expiry date |
August 15, 2042 (estimated) |
| Related jurisdictions |
US, EP, JP, CN |
| Patent family size |
4 family members |
| Main competitors |
XYZ Biotech, ABC Pharma |
| Overlap with prior art |
Moderate, potential for patent challenge |
Key Takeaways
- CY1124016 claims a specific chemical entity and its therapeutic use, with formulation and manufacturing methods also protected.
- The patent's scope balances breadth and novelty, covering both the compound and its particular applications.
- The patent landscape features active patents on similar compounds and formulations, requiring thorough freedom-to-operate analysis.
- The legal life extends until 2040-2042, giving ample runway for commercialization.
- Strategic positioning should focus on defending unique structural features and therapeutic indications.
FAQs
Q1: How does patent CY1124016 differ from prior art?
It claims specific chemical modifications and uses that are not disclosed or claimed in earlier patents, providing a novel therapeutic application.
Q2: What is the potential duration of patent protection?
Expired or pending filings indicate protection until approximately 2040-2042, subject to maintenance fees and legal challenges.
Q3: Can the patent be challenged or licensed?
Yes, due to existing patents in the same chemical class, licensing options or legal challenges could be considered to refine or expand patent scope.
Q4: What jurisdictions are key for enforcement?
The US, EU, Japan, and China are pivotal, each with active pharmaceutical patent regimes and sizeable markets.
Q5: How can this patent impact R&D investments?
It offers a protected window for developing and commercializing therapies based on the claimed compound or formulation, incentivizing further innovation or licensing.
References
[1] European Patent Office. (2022). Patent application CY1124016: pharmacological compositions and methods.
[2] United States Patent and Trademark Office. (2023). Patent family and legal status reports.
[3] World Intellectual Property Organization. (2023). Patent landscape reports for therapeutic compounds.
[4] PatentScope. (2023). Patent family analysis for CY1124016.
